Lurasidone: a clinical overview

The Journal of Clinical Psychiatry
John M Kane


Lurasidone is a new second-generation (atypical) antipsychotic approved for the treatment of schizophrenia in adults. The recommended dose is 40-80 mg given once daily, with no titration needed. Lurasidone should be taken with food. The tolerability profile of lurasidone is noteworthy in terms of a good weight and metabolic profile and no cardiovascular adverse effects such as orthostatic hypotension or prolongation of the QTc interval. Lurasidone is associated with some somnolence, akathisia, nausea, and parkinsonism, especially early in treatment. Its preclinical profile suggested it might be helpful for cognitive or depressive symptoms; early findings have shown some benefit in these areas, but additional studies are needed. Lurasidone may be particularly helpful for patients with schizophrenia who are overweight or have endocrine problems (diabetes, dyslipidemia) or comorbid cardiovascular conditions.


Jun 8, 2012·Drug Design, Development and Therapy·Norio Yasui-Furukori
Jun 19, 2012·Current Psychiatry Reports·Brett A EnglishStanford Jhee

Related Concepts

Metabolic Process, Cellular
Antipsychotic Effect
Hypotension, Orthostatic
Adverse Effects
Parkinsonian Disorders
Long QT Syndrome

Related Feeds


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

The Journal of Clinical Psychiatry
Leslie Citrome
Expert Review of Neurotherapeutics
Joshua T Kantrowitz, Leslie Citrome
Issues in Mental Health Nursing
Shambria F Nolan, Marian W Roman
© 2020 Meta ULC. All rights reserved